Analysis: Takeda Buy Of Amgen Subsidiary Could Trigger Sell Off Of Japanese Units

Takeda's acquisition of U.S. biotech Amgen's Japanese subsidiary could signal a shift of foreign drug maker focus from maintaining subsidiaries in Japan to selling them so they can focus instead on China and India. An official at a major Japanese pharmaceutical said many of the world's biggest drug makers are considering selling their units in Japan. Several years ago, the same drug makers were emphasizing expansions into Japan, then the world's second-largest drug market. The companies have since learned Japan has a lengthy and costly process of clinical trials. (Click here for more - a subscription may be required